Prostate cancer is the most prevalent type of cancer for U.S. men (about 192,280 new cases this year), and it is the second highest contributor to cancer death among men in the U.S. (27,360 will die of it this year). A major issue in prostate cancer detection and therapy is that we currently have no method to reliably distinguish aggressive prostate cancer from non-aggressive prostate cancer using available biomarkers. This leads to significant unnecessary suffering among prostate cancer patients and leads to massive unnecessary health care expenditures. We hypothesize that specific glycoproteins and glycan modifications of glycoproteins can be used to distinguish aggressive from non-aggressive prostate cancer in tissue and serum. We propose in four specific aims to develop novel glycoprotein biomarkers that can detect aggressive cancer in primary tissues and pre-surgical serum.
In Aim 1, we will analyze glycans and glycoproteins from metastatic, aggressive cancer, non-aggressive cancer, and normal prostate tissues to identify glycoproteins associated with aggressive prostate cancer.
In Aim 2, we will develop highly sensitive, specific, and high throughput MS based SRM assays for the candidate glycopeptides identified from Aim 1. We will optimize the SRM assays and determine their analytical performance, and construct an SRM database and make the assay available to the research community.
In Aim 3, we will use the developed SRM assays from Aim 2 to verify the glycoproteins for aggressive prostate cancer in additional prostate cancer tissues and validate these tissue glycoproteins using tissue microarrays.
In Aim 4, we will use the SRM assays to determine which of the verified glycopeptides in tissues can be detected in patient's sera, and therefore can be used as serum tests. Then, we will apply the SRM assays to the serum samples and develop validate multivariate models for detecting aggressive prostate cancer using serum tests. In addition, we will validate these markers and multivariate models using an independent testing set of prostate cancer serum. If successful, the identified and validated biomarkers will be tested by EDRN biomarker reference (BRL) and clinical validation (CVC) laboratories in retrospective and prospective studies. Biomarkers capable of distinguishing aggressive from nonaggressive prostate cancer would present men with non-aggressive prostate cancer from overtreatment, and could allow men with aggressive cancer to receive appropriate treatment earlier in the course of their diseases. SRM = selected reaction monitoring

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (M1))
Program Officer
Kagan, Jacob
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Aiyetan, Paul; Zhang, Bai; Zhang, Zhen et al. (2014) XGlycScan: An Open-source Software For N-linked Glycosite Assignment, Quantification and Quality Assessment of Data from Mass Spectrometry-based Glycoproteomic Analysis. MOJ Proteom Bioinform 1:
Ao, Ming-Hui; Zhang, Hui; Sakowski, Lynne et al. (2014) The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer. Hum Pathol 45:926-34
Wang, Xiangchun; Chen, Jing; Li, Qing Kay et al. (2014) Overexpression of ? (1,6) fucosyltransferase associated with aggressive prostate cancer. Glycobiology 24:935-44
Aiyetan, Paul; Zhang, Bai; Chen, Lily et al. (2014) M2Lite: An Open-source, Light-weight, Pluggable and Fast Proteome Discoverer MSF to mzIdentML Tool. J Bioinform 1:40-49
Harlan, Robert; Zhang, Hui (2014) Targeted proteomics: a bridge between discovery and validation. Expert Rev Proteomics 11:657-61
Liu, Yansheng; Chen, Jing; Sethi, Atul et al. (2014) Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol Cell Proteomics 13:1753-68
Sun, Shisheng; Zhou, Jian-Ying; Yang, Weiming et al. (2014) Inhibition of protein carbamylation in urea solution using ammonium-containing buffers. Anal Biochem 446:76-81
Yang, Shuang; Zhang, Hui (2014) Glycomic analysis of glycans released from glycoproteins using chemical immobilization and mass spectrometry. Curr Protoc Chem Biol 6:191-208
Toghi Eshghi, Shadi; Yang, Shuang; Wang, Xiangchun et al. (2014) Imaging of N-linked glycans from formalin-fixed paraffin-embedded tissue sections using MALDI mass spectrometry. ACS Chem Biol 9:2149-56
Tian, Yuan; Zhang, Hui (2013) Characterization of disease-associated N-linked glycoproteins. Proteomics 13:504-11

Showing the most recent 10 out of 33 publications